The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States.
about
Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview.Characterization of NS5A and NS5B Resistance-Associated Substitutions from Genotype 1 Hepatitis C Virus Infected Patients in a Portuguese Cohort.Population Health and Cost-Effectiveness Implications of a "Treat All" Recommendation for HCV: A Review of the Model-Based Evidence
P2860
The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The cost-effectiveness of test ...... regimens in the United States.
@en
The cost-effectiveness of test ...... seline in genotype 1a-infected
@nl
type
label
The cost-effectiveness of test ...... regimens in the United States.
@en
The cost-effectiveness of test ...... seline in genotype 1a-infected
@nl
prefLabel
The cost-effectiveness of test ...... regimens in the United States.
@en
The cost-effectiveness of test ...... seline in genotype 1a-infected
@nl
P2093
P2860
P356
P1476
The cost-effectiveness of test ...... regimens in the United States
@en
P2093
E H Elbasha
M N Robertson
P2860
P304
P356
10.1111/APT.13882
P407
P577
2016-12-01T00:00:00Z